Plus, news about Alnylam, Hutchmed, Wave Life Sciences and Matinas BioPharma:
Boehringer Ingelheim ends work with Gubra on obesity drug: The German drugmaker stopped developing Gubra’s long-acting neuropeptide Y receptor type ...
↧